"Healthy China 2030" 2022 Rheumatology and Immune Correspondence Diagnosis and Treatment Training Series City Conference -Jiangsu Station's first confession!

On June 19, 2022, "Healthy China 2030" 2022 rheumatism and immune disease standardized diagnosis and treatment training series cities will be held smoothly online online. The project is sponsored by the National Health and Health Commission Medical, Health Science and Technology Development Research Center (hereinafter referred to as the "National Health and Health Commission Science and Technology Development Center"). Standardized construction and development of disease diagnosis and treatment.

Zhang Jing, the person in charge of the Transformation Department of the Science and Technology Development Center of the National Health and Health Commission, Zhang Jing, Standing Committee Member of the Chinese Medical Association Rheumatology Branch, Chairman of the Jiangsu Provincial Rheumatology Medical Association, Professor Zhang Miaojia of Rheumatology and Immunology Department of Nanjing Medical University, Chinese Medical Medicine, Chinese Medical Medicine Member of the Rheumatology Branch, Chairman of the Rheumatology Branch of the Jiangsu Medical Association, Professor Feng Xuebing, Feng Xuebing Hospital affiliated to Nanjing University Medical College, and more than 20 domestic experts and scholars from Jiangsu, Anhui, and Henan attended the meeting Essence

At the beginning of the meeting, the host of the conference, Professor Zhang Miaojia, delivered a speech, saying that the conference provided a professional academic exchange platform for experts and scholars in the field, which will greatly help the development of rheumatism and immunology disciplines in my country. I wish the conference a complete success!

Zhang Jing, Director of the Response Transformation Department of the Science and Technology Development Center of the National Health and Health Commission, congratulated the conference to be held smoothly, stating that with the continuous improvement of my country's medical level, rheumatism and immunity have attracted more and more attention in clinical practice. However, the construction of rheumatism and immunotheisms starts late, less than other disciplines from other disciplines. Patients have low awareness of diseases and insufficient awareness of the importance of disease diagnosis and treatment. Based on the above background, the Science and Technology Development Center has launched a standardized diagnosis and treatment training project of rheumatism and immune disease, inviting experts, key provinces and urban medical workers to participate in this education and training activities. This project was launched in Beijing in May. Jiangsu is the first stop of a series of urban conferences. Next, it will continue to be carried out in other key provinces and cities across the country. Develop, improve diagnosis and treatment capabilities and standardization levels.

Rheumatology and immunity, thousands of paths, clinical diagnosis and treatment, evidence -based first! The first meeting of Jiangsu Station in the "Rheumatology and Evidence Journey" series will begin!

Drum Tower Hospital Affiliated to Nanjing University Medical College

Professor Zhang Huayong's interpretation

"" Multi -Terminal Terms in Rheumatoid Arthritis Management "

This meeting is divided into two links. In the first part of the academic session, Professor Zhang Huayong from the Drum Tower Hospital of Nanjing University Medical College explained the "multi -tube in the" multi -tube of rheumatoid arthritis management in the management of rheumatoid arthritis management and other aspects. Trinity "". Professor Zhang Huayong pointed out that RA is heterogeneous, and multi -target treatment may break through the healing dilemma. In actual clinical treatment, only less than 30% of patients with RA have reached standards, and the choice of drug solutions still has room for optimization. Understanding the heterogeneity of RA cells and molecular characteristics helps to develop safe and effective treatment methods. Finding biomarkers is the main way for RA precision treatment.

The first part of the discussion session was chaired by Professor Zhang Miaojia, a member of the Standing Committee of the Chinese Medical Association Rheumatism Branch, the president of the Jiangsu Rheumatology Medical Association, and Professor Zhang Miaojia of the Department of Rheumatology and Immunology of Nanjing Medical University, Professor Zheng Chaohui of Zhengzhou University First Affiliated Hospital, Xuzhou Professor Yin Songlou, an affiliated hospital of the Medical University University, started with a fierce discussion on the heterogeneity, individual differentiation and joint treatment plan for RA's heterogeneity, individual differentiation and joint treatment plan.

Changzhou First People's Hospital

Professor Wu Min interpret

"Disease Management under RA-ILD Dual Mids Objective Objectives"

The theme of the second part of the academic sharing session is "Disease Management under the RA-ILD Dual Mids Objective Goals", which is interpreted by Professor Wu Min, Professor Wu Min, the First People's Hospital of Changzhou. Professor Wu Min mentioned that the mortality rate of patients with RA-ILD (RA-ILD) is about 3 times that of patients with inferior lung disease. Explanation of dual -standard targets. RA's disease activity is related to the emergence and progress of ILD, and the good control of arthritis activity is important to prevent the acute deterioration of RA-ILD. RA-ILD's screening and diagnostic strategies need to focus on the goal of dual standards.

The second part of the academic discussion session was chaired by Professor Feng Xuebing, Chairman of the Rheumatology Branch of the Chinese Medical Association, chairman of the Jiangsu Medical Association Rheumatology Branch, Professor Feng Xuebing, Drum Tower Hospital of Nanjing University School of Medicine, Professor Yuan Fenghong of Wuxi People's Hospital, No. 1 Eight guests including Professor Wang Yan, an Affiliated Hospital, shared and discussed their previous diagnosis and treatment experience from the ILD screening of RA patients and the diagnosis and treatment strategies adopted by RA-ILD.

Professor Feng Xuebing and Professor Zhang Miaojia concluded the conference concluding speech

At the end of the meeting, Professor Feng Xuebing and Professor Zhang Mujia summarized the meeting and made a closing speech.In the past 30 years, the development of China's rheumatism and immunology disciplines has made remarkable development.However, the construction of rheumatism and immune medical personnel teams still needs to be improved.The "2022 Rheumatology and Immunosis Diagnosis and Treatment Training Project" hosted by the Science and Technology Development Center of the National Health and Health Commission has provided strong support for the construction and development of future disciplines.The two professors once again thanked Director Zhang Jing and all the guests for the arrival to express their sincere congratulations on the successful conclusion of the "Rheumatology and Evidence-based Journey-Jiangsu Station", and wished the subsequent "Rheumatology and Evidence Journey" series of cities will go smoothly.Carry out!Big coffee gathers, sharing academic feasts; ideological collisions lead the clinical diagnosis and treatment.After the successful convening of the Beijing Startup Society, the "Rheumatology and Evidence Travel" series city meeting-Jiangsu Station's first confession!

Capture: Liu Zibo

Edit: Liu Zibo

- END -